These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28322941)

  • 1. Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
    Kashihara Y; Ieiri I; Yoshikado T; Maeda K; Fukae M; Kimura M; Hirota T; Matsuki S; Irie S; Izumi N; Kusuhara H; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2688-2694. PubMed ID: 28322941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose.
    Ieiri I; Doi Y; Maeda K; Sasaki T; Kimura M; Hirota T; Chiyoda T; Miyagawa M; Irie S; Iwasaki K; Sugiyama Y
    J Clin Pharmacol; 2012 Jul; 52(7):1078-89. PubMed ID: 21593283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1.
    Medwid S; Li MMJ; Knauer MJ; Lin K; Mansell SE; Schmerk CL; Zhu C; Griffin KE; Yousif MD; Dresser GK; Schwarz UI; Kim RB; Tirona RG
    Drug Metab Dispos; 2019 Aug; 47(8):832-842. PubMed ID: 31123035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
    Safar Z; Kis E; Erdo F; Zolnerciks JK; Krajcsi P
    Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):313-328. PubMed ID: 30856014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
    Kim TE; Shin D; Gu N; Jung BH; Kim J; Cho YM; Yu KS; Cho JY
    Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):195-201. PubMed ID: 28627804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting inhibitory effect of apple and orange juices, but not grapefruit juice, on OATP2B1-mediated drug absorption.
    Shirasaka Y; Shichiri M; Murata Y; Mori T; Nakanishi T; Tamai I
    Drug Metab Dispos; 2013 Mar; 41(3):615-21. PubMed ID: 23264447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
    Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions.
    Shirasaka Y; Shichiri M; Mori T; Nakanishi T; Tamai I
    J Pharm Sci; 2013 Sep; 102(9):3418-26. PubMed ID: 23794501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.
    Shirasaka Y; Mori T; Murata Y; Nakanishi T; Tamai I
    Pharm Res; 2014 Aug; 31(8):2035-43. PubMed ID: 24549825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
    Sasabe H; Shimokawa Y; Shibata M; Hashizume K; Hamasako Y; Ohzone Y; Kashiyama E; Umehara K
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3497-508. PubMed ID: 27021329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion.
    Akamine Y; Miura M; Komori H; Tamai I; Ieiri I; Yasui-Furukori N; Uno T
    Drug Metab Pharmacokinet; 2015 Oct; 30(5):352-7. PubMed ID: 26213156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of OATP2B1 on Pharmacokinetics of Atorvastatin Investigated in
    Kinzi J; Hussner J; Seibert I; Vythilingam M; Vonwyl C; Gherardi C; Detampel P; Schwardt O; Ricklin D; Meyer Zu Schwabedissen HE
    Drug Metab Dispos; 2024 Aug; 52(9):957-965. PubMed ID: 39038952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
    Karibe T; Hagihara-Nakagomi R; Abe K; Imaoka T; Mikkaichi T; Yasuda S; Hirouchi M; Watanabe N; Okudaira N; Izumi T
    Pharm Res; 2015 May; 32(5):1634-47. PubMed ID: 25380981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of inhibitory duration of grapefruit juice on organic anion-transporting polypeptide and cytochrome P450 3A4.
    Tanaka S; Uchida S; Miyakawa S; Inui N; Takeuchi K; Watanabe H; Namiki N
    Biol Pharm Bull; 2013; 36(12):1936-41. PubMed ID: 24292052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
    Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
    J Pharm Sci; 2015 Sep; 104(9):3039-48. PubMed ID: 25639366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
    Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
    Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
    Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
    Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta.
    Grube M; Reuther S; Meyer Zu Schwabedissen H; Köck K; Draber K; Ritter CA; Fusch C; Jedlitschky G; Kroemer HK
    Drug Metab Dispos; 2007 Jan; 35(1):30-5. PubMed ID: 17020956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.
    Hua WJ; Hua WX; Fang HJ
    Cardiovasc Ther; 2012 Oct; 30(5):e234-41. PubMed ID: 21884024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.